Co-Diagnostics Inc(CODX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -22.46 | Insider Own | 2.61% | Shs Outstand | 8.8M | Perf Week | -18.96% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 73.23% | Insider Trans | - | Shs Float | 8.6M | Perf Month | -65.45% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -1.25 | Inst Own | 6.75% | Short Float | 7.64% | Perf Quarter | -74.83% |
| Income | -0.05B | P/S | 6.45 | EPS this Y | 91.21% | Inst Trans | 7.5% | Short Ratio | 1.8 | Perf Half Y | -76.1% |
| Sales | 0.00B | P/B | 0.15 | EPS next 5Y | 80.05% | ROA | -149.25% | Short Interest | 0.66M | Perf YTD | -92.49% |
| Book/sh | 2.61 | P/C | 0.92 | EPS past 3/5Y | -37.47% - | ROE | -174.77% | 52W High | -97.25% ($13.80) | Perf Year | -96.87% |
| Cash/sh | 0.41 | P/FCF | - | Sales past 3/5Y | -76.97% -64.54% | ROIC | -342.8% | 52W Low | 8.57% ($0.35) | Perf 3Y | -99.05% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 33.16% | Gross Margin | -170.74% | Volatility(W/M) | 13.01% 13.89% | Perf 5Y | -99.85% |
| Dividend TTM | - | EV/Sales | 2.9 | Sales Y/Y TTM | -9.18% | Oper. Margin | -5857.07% | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.52 | EPS Q/Q | 79.18% | Profit Margin | -9100% | RSI (14) | 21.84 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.81 | Sales Q/Q | 1.98% | SMA20 | -44.94% ($0.69) | Beta | 3.19 | Target Price | $4 |
| Payout | - | Debt/Eq | 0.14 | Earnings | 2026/11/12 | SMA50 | -59.82% ($0.95) | Rel Volume | 0.97 | Prev Close | $0.35 |
| Employees | 115 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | - | SMA200 | -82.52% ($2.17) | Avg Volume(3M) | 0.36M | Price | $0.38 |
| IPO | 2017/7/12 | Option/Short | No/Yes | Trades | 635 | Volume | 354,005 | Change | 7.56% |
🧬 This is a US medical device company that develops PCR (polymerase chain reaction)-based molecular diagnostic technology. Through its proprietary Co-Dx PCR platform, it creates infectious disease diagnostic tests that can be used in both clinical and at-home settings, with a key feature being the ability to test for a wide range of infectious diseases—including COVID-19, influenza, tuberculosis, hepatitis, and HPV—all on a single device.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded about as much as usual. That is 97% of its average volume.
Next earnings report: November 12
8 days to go.
CODX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +91.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $645. Peers typically go for $145. It is about in line with its own 1-year average.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #130 of 140 in the industry
Based on market cap of $3M.
VVOS#129 Vivos Therapeutics Inc $4M PER - CODX#130 Co-Diagnostics Inc $3M PER - 
AMIX#131 Autonomix Medical Inc $3M PER - 
NUWE#132 Nuwellis Inc $3M PER - 
AIDX#133 20/20 Biolabs Inc $3M PER - 
FAQ
What kind of company is CODX?
CODX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of CODX?
The market cap of CODX is approximately $3M, ranking 5,707 within its sector.
What is the 52-week high and low for CODX?
CODX has recorded a 52-week high of $13.80 and a low of $0.35.
